Patents by Inventor Christian R. Noe
Christian R. Noe has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230414505Abstract: The invention relates to an emulsion, e.g. in the form of a salve or a cream, with an aqueous phase and an oil phase, containing an NSAID, characterised in that: (a) the NSAID in the aqueous phase is in a concentration range that corresponds to half to a tenth of the standard concentration for these active substances; (b) the weight ratio of the water-to-oil phase in said emulsion is between the values 2.0 and 2.7; and (c) the pH value of the emulsion is not below the value 6.5 and not above 8.5, preferably in the region of between 7.0 and 8.0, particularly for application in the topical treatment of vaginal fungal infections.Type: ApplicationFiled: August 14, 2023Publication date: December 28, 2023Applicant: ProFem GmbHInventors: Marion NOE, Christian R. NOE
-
Patent number: 11779538Abstract: The invention relates to an emulsion, e.g. in the form of a salve or a cream, with an aqueous phase and an oil phase, containing an NSAID, characterised in that: (a) the NSAID in the aqueous phase is in a concentration range that corresponds to half to a tenth of the standard concentration for these active substances; (b) the weight ratio of the water-to-oil phase in said emulsion is between the values 2.0 and 2.7; and (c) the pH value of the emulsion is not below the value 6.5 and not above 8.5, preferably in the region of between 7.0 and 8.0, particularly for application in the topical treatment of vaginal fungal infections.Type: GrantFiled: November 14, 2018Date of Patent: October 10, 2023Assignee: ProFem GmbHInventors: Marion Noe, Christian R. Noe
-
Publication number: 20230233497Abstract: The invention relates to a composition comprising at least one C4 component and at least one C3 component, wherein the C4 component consists of ornithine and/or arginine or a suitable derivative of ornithine and/or arginine, wherein the C3 component consists of methionine and/or S-adenosylmethionine or a suitable derivative of methionine and/or S-adenosylmethionine, and wherein the molar ratio between the C3 component and the C4 component is between 1:5 and 5:1. The invention further relates to a nutritional supplement.Type: ApplicationFiled: March 3, 2021Publication date: July 27, 2023Applicant: BM Health GmbHInventor: Christian R. NOE
-
Publication number: 20230128434Abstract: The present application relates to pharmaceuticals for inhalation, containing aurothioglucose, and to an inhaler, preferably a powder inhaler, dosing inhaler or atomizer containing such pharmaceuticals. The application provides these pharmaceuticals for use in the prevention and therapy of pulmonary diseases, in particular infectious and inflammatory-infectious pulmonary diseases.Type: ApplicationFiled: March 15, 2021Publication date: April 27, 2023Inventors: Christian R. NOE, Marion NOE-LETSCHNIG
-
Publication number: 20220395008Abstract: The invention relates to a glucose-containing sweetening mixture, comprising or consisting of glucose and at least one glucose-free sweetener, wherein the sweetening mixture has a sweetness between 3.0 and 5.0, in particular between 3.5 and 4.5. The invention further relates to a food product containing this sweetening mixture.Type: ApplicationFiled: November 10, 2020Publication date: December 15, 2022Applicant: BM HEALTH GMBHInventor: Christian R. NOE
-
Patent number: 11266600Abstract: The invention relates to an emulsion for the topical treatment of dermal infections and mucosal infections, in particular of urogenital infectious diseases, characterized in that an antimicrobial agent and an anti-adhesive agent, preferably an NSAID, are used in combination.Type: GrantFiled: November 14, 2018Date of Patent: March 8, 2022Assignee: ProFem GmbHInventors: Marion Noe, Christian R. Noe
-
Publication number: 20200281852Abstract: The invention relates to an emulsion, e.g. in the form of a salve or a cream, with an aqueous phase and an oil phase, containing an NSAID, characterised in that: (a) the NSAID in the aqueous phase is in a concentration range that corresponds to half to a tenth of the standard concentration for these active substances; (b) the weight ratio of the water-to-oil phase in said emulsion is between the values 2.0 and 2.7; and (c) the pH value of the emulsion is not below the value 6.5 and not above 8.5, preferably in the region of between 7.0 and 8.0, particularly for application in the topical treatment of vaginal fungal infections.Type: ApplicationFiled: November 14, 2018Publication date: September 10, 2020Applicant: ProFem GmbHInventors: Marion NOE, Christian R. NOE
-
Publication number: 20200281853Abstract: The invention relates to an emulsion for the topical treatment of dermal infections and mucosal infections, in particular of urogenital infectious diseases, characterized in that an antimicrobial agent and an anti-adhesive agent, preferably an NSAID, are used in combination.Type: ApplicationFiled: November 14, 2018Publication date: September 10, 2020Applicant: ProFem GmbHInventors: Marion NOE, Christian R. NOE
-
Publication number: 20200146327Abstract: A dietetic preparation for preventing or alleviating a glucose deficiency in the brain of humans or mammals, wherein the preparation contains glucose and at least one glucose-free sweetener, wherein the mixture of glucose and glucose-free sweetener has a sweetening power of 1.5 to 3.0, in particular 2.0.Type: ApplicationFiled: May 29, 2018Publication date: May 14, 2020Applicant: BM Health GmbHInventor: Christian R. Noe
-
Publication number: 20190100548Abstract: The invention relates to anthracycline derivative compounds for treating tumor diseases, and related methods, compositions, and kits.Type: ApplicationFiled: December 3, 2018Publication date: April 4, 2019Inventors: Christian R. Noe, Michael Sonntagbauer, Sébastien Queva, Ernst Urban
-
Patent number: 10144753Abstract: The invention relates to anthracycline derivative compounds for treating tumor diseases, and related methods, compositions, and kits.Type: GrantFiled: October 15, 2013Date of Patent: December 4, 2018Assignee: Produkem Molekulares Design GMBHInventors: Christian R. Noe, Michael Sonntagbauer, Sébastien Queva, Ernst Urban
-
Patent number: 9968686Abstract: The invention relates to an antisense or siRNA oligonucleotide or conjugate with improved pharmacokinetic properties, methods of producing the same as well as the use of such compounds and conjugates, e.g. as pharmaceutical composition, a pharmaceutical kit, a medicament or a tool in biomedical research. The conjugates of the invention have the formula I being P-(L-S—S—Y—X)n, wherein P represents a natural, artificial and/or modified oligonucleotide, L represents a linker group attached to one or more nucleosides at any position within the oligonucleotides sequence; S represents sulfur; X represents a ligand; Y represents a spacer and n is an integer ranging from 1 to the oligonucleotide length of P.Type: GrantFiled: September 9, 2014Date of Patent: May 15, 2018Assignee: UNIVERSITY OF VIENNAInventors: Christian R. Noe, Mehrdad Dirin, Johannes Winkler, Bodo Lachmann, Ernst Urban
-
Publication number: 20160193354Abstract: The invention relates to an antisense or siRNA oligonucleotide or conjugate with improved pharmacokinetic properties, methods of producing the same as well as the use of such compounds and conjugates, e.g. as pharmaceutical composition, a pharmaceutical kit, a medicament or a tool in biomedical research. The conjugates of the invention have the formula I being P-(L-S-S-Y-X)n, wherein P represents a natural, artificial and/or modified oligonucleotide, L represents a linker group attached to one or more nucleosides at any position within the oligonucleotides sequence; S represents sulfur; X represents a ligand; Y represents a spacer and n is an integer ranging from 1 to the oligonucleotide length of P.Type: ApplicationFiled: September 9, 2014Publication date: July 7, 2016Inventors: Christian R. Noe, Mehrdad Dirin, Johannes Winkler, Bodo Lachmann, Ernst Urban
-
Publication number: 20150252069Abstract: The invention relates to compounds of the general formula (I) in which R1 is a hydrogen atom, a hydroxy or methoxy group, a halogen atom, or an NO2 group; R2 is a hydrogen atom, a hydroxy or methoxy group, or an acyl or aroyl group; R3 is hydrogen, trifluoroacetyl (C(?O)CF3), or p-nitrobenzoyl (C(?O)PhNO2), and in each case the wavy line represents both possible configurations of —OR3 relative to the skeleton; Y is [C(?O)], [C(?N)—OH], [CH—OH], or [CH—NR5R6] in the two possible stereoisomer arrangements, wherein R5 and R6 either each represent a hydrogen atom or a hydrogen atom and a trifluoroacetyl group (TFA); X=O, S, or NR, in which R=hydrogen or a C1 to C4 alkyl group; and R4 is an unbranched or branched alkyl or heteroalkyl chain with a chain length of 1 to 19 elements, maximally 6 heteroatoms (O, N, S) being separated from one another in any combination by at least two carbon atoms.Type: ApplicationFiled: October 15, 2013Publication date: September 10, 2015Inventors: Christian R. Noe, Michael Sonntagbauer, Sébastien Queva, Ernst Urban
-
Publication number: 20080249119Abstract: The invention relates to homogemcitabines of general formula (2), with the meanings for the substituents as given in claim 1, method for production thereof, use for the production of the active agent gemcitabin and the use thereof for the production of medicaments for the treatment of proliferative diseases. The invention further relates to novel intermediates, as used in the inventive method.Type: ApplicationFiled: July 20, 2006Publication date: October 9, 2008Applicant: PHARMACON-FORSCHUNG UND BERATUNG GMBHInventors: Christian R. Noe, Muhamed Jasic, Hermann Kollmann, Karmin Saadat
-
Publication number: 20080221340Abstract: The subject of the invention is a process for the production of the racemic active ingredient nebivolol, in which diastereomeric cyanohydrins are produced, separated, and the separated diastereomers are coupled to one another after a transformation, preferably a partial or complete reduction of the cyano group or a Pinner saponification.Type: ApplicationFiled: July 17, 2006Publication date: September 11, 2008Applicant: Pharmacon Forschung und Bearatung GmbHInventors: Christian R. Noe, Muhamed Jasic, Hermann Kollmann, Bodo Lachmann
-
Patent number: 4739082Abstract: Enantiomerically pure mono acetal-protected diols of the formula ##STR1## wherein A, B, C and D are hydrogen or a methyl group in any combination, M and N are aliphatic or araliphatic hydrocarbons, m and n are the numbers 0, 1 or 2, whereby the total of m plus n must be the number 1 or 2, their preparation and use for the syntheses of the pheromones (1R-exo)-Brevicomin, (1S-exo)-Brevicomin, (1R-endo)-Brevicomin and (1S-endo)-Brevicomin.Type: GrantFiled: March 29, 1985Date of Patent: April 19, 1988Assignee: Chemie Linz AktiengesellschaftInventors: Christian R. Noe, Max Knollmuller